WADA Releases 2026 Annual Report: Testing Rises, the Curve Has Slowed, and the Gap Behind It

In the 297,965 test samples recorded by the World Anti-Doping Agency (WADA) in 2026, only 0.78 percent returned an adverse result. For three straight years that rate has barely moved: 0.77 percent in 2026, 0.80 percent in 2026, 0.78 percent in 2026, a band just 0.03 percentage points wide. A metric that stands still for three years says more than one that spikes. It forces the analyst to ask about the structure underneath, rather than chase the headline. The 2026 annual report's headline points elsewhere: testing volume rose. The movement worth reading is in the pace, not in the total. WADA published its 2026 annual report, covering testing, compliance and finance across the system. The 297,965 samples of 2026 follow 288,865 samples in 2026, a rise of roughly 9,100 samples. The pace slowed sharply: 12.5 percent growth in 2026–2026, then just 3.2 percent in 2026–2026. One detail matters for reading the document. A report labelled 2026 typically summarises the previous year's activity, meaning 2026 data. The testing series runs continuously from 2026 to 2026, giving a baseline long enough to compare trends rather than read isolated points. For an analyst, a seven-year series is worth far more than a single-year summary. For swimming, this is an indirect but far from trivial story. Swimming is a heavy sample-consuming sport, with testing programmes spanning 50m to 1500m events, short course and long course alike. Any change in national-level testing capacity reaches this sport first, because a swimming sample is not cheap and the multi-event structure keeps sample volumes high. I have followed sports governance reports since 2026, when I worked as a swimming reporter. When the pandemic froze the world, the transfer market became a place where numbers lost their meaning. I learned that a governance report only has value when the reader can separate the trend line from the data point. Some findings do not come from luck, but from being willing to read the movements the crowd skips. The testing-volume curve shows signs of resource saturation. When growth falls from 12.5 percent to 3.2 percent in a single year, the cause usually comes from one of two sides: either testing demand has been met, or operational capacity has hit a ceiling. The report does not separate these, but the financial section at the back hints at the second. Beyond testing, WADA published its compliance audit results. The number of audits is just nine. Average non-conformities fell from 25.5 to 20, a recorded improvement. But inside nine audits, that improvement rests on a thin evidence base and is easily shaped by sample selection. The more notable detail is the composition. Testing-related non-conformities make up 45 percent of all findings, up 11 percent year on year, with 23 percent classified as critical. The average score improved, but the most important axis worsened. This is data I know well from swimming analysis: the total time can improve while the final sprint slows down. A summary metric does not disprove the problem, it merely hides it. Non-conformity must be read narrowly. It is a finding that an anti-doping organisation or a government has failed to meet the requirements of the code and international standards. It does not mean an athlete cheated. It speaks to process, paperwork, sample collection and storage capacity. When the testing-related share of non-conformities rises 11 percent, the problem sits in the collection chain, not in the laboratory. The financial section opens a clearer picture. WADA recorded a shortfall of 8.3 million US dollars against budget. The United States has not paid 3.8 million USD, and Russia owes 3.9 million USD. The rare bright spot is a net surplus of 1.2 million USD, showing the agency squeezed spending considerably. The coexistence of a net surplus and a large shortfall is a telling signal. It usually means costs were cut or spending was deferred. For an organisation whose output is testing capacity, cutting costs at the very moment coverage is meant to expand carries a price. The two large arrears come from the two countries with the greatest political weight in world sport. The report states the facts without attributing motive, so I will not speculate either. Structurally, though, a system whose enforcement body depends on money outside its control has a built-in weakness. In parallel, WADA recorded a strategic shift. Its investigations unit ran more than 250 operations, dismantled 88 laboratories and seized over 90 tonnes. Part of the resource base is moving from mass testing toward targeted investigation. The direction has its logic. Investigations target networks, supply sources and organisers. Mass testing targets individuals. When budgets tighten, shifting toward investigations preserves effectiveness per dollar spent. But it raises a coverage question: if mass testing slows, who gets missed? At the rule level, the 2027 World Anti-Doping Code was adopted in Busan, South Korea, and takes effect on January 1, 2027. Before that, WADA and the Athlete Council ran consultations with more than 600 athletes and commissions from over 60 countries and more than 70 sports. The consultation is impressive in scale, but the report does not say how far athlete input changed the substance of the text. Scale does not equal influence. A broad consultation can be both a legitimacy-building step and a way to reduce later dispute risk. Data does not judge, but it points me to the questions others forget. The counterintuitive point sits here: the conventional reading holds that more testing means cleaner sport. That logic has merit, since broader coverage catches more cases. But three years of data show coverage expanding while the detection rate stays flat. If the true positive rate really is stable around 0.78 percent, then adding 9,100 samples produces roughly 71 extra cases. A small number against the size of the system, and far smaller than a headline about rising testing might suggest. A second reading: the system is selecting samples more precisely, targeting higher-risk groups, so the detection rate holds even as samples rise. The report provides no data to confirm this. Between the two readings, the available data cannot pick a side. The biggest blind spot lies in the gap between now and January 1, 2027. The new code has been adopted but is not yet in force. The 2026–2026 window is a transition zone where old-standard behaviour persists. National anti-doping organisations that are unprepared gain extra time, but also extra incentive to delay. And when funding is threatened by two large arrears, testing capacity in poorly resourced federations becomes a structural weak point. In swimming, developing nations are usually where out-of-competition coverage is thinnest. A swimmer in a country with a tight anti-doping budget will be tested less than a peer in a wealthy country, even though the law applies equally to all. This is the point analytical models often skip, because it does not live in performance data. It lives in governance data. An injury is where every analytical model must bow, and also where I have learned the most. For the global anti-doping system, this year's injury is called a financial shortfall. What is worth tracking in the next cycle is not the total sample count but four signals: whether testing-volume growth turns negative, whether the adverse-finding rate breaks above 0.85 percent, whether the testing-related non-conformity share passes 45 percent, and whether the US and Russian contributions are resolved. None of these four signals appears in the report's headline. They sit in the tables behind it. And one question stays open: by 2027, will the system have enough resources to enforce the code it has just adopted?